Coherus BioSciences (FRA:8C5) Common Stock : €0.0 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Coherus BioSciences Common Stock?

Coherus BioSciences's quarterly common stock stayed the same from Sep. 2023 (€0.0 Mil) to Dec. 2023 (€0.0 Mil) and stayed the same from Dec. 2023 (€0.0 Mil) to Mar. 2024 (€0.0 Mil).

Coherus BioSciences's annual common stock increased from Dec. 2021 (€0.0 Mil) to Dec. 2022 (€0.0 Mil) and increased from Dec. 2022 (€0.0 Mil) to Dec. 2023 (€0.0 Mil).

Coherus BioSciences Common Stock Historical Data

The historical data trend for Coherus BioSciences's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Coherus BioSciences Common Stock Chart

Coherus BioSciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Common Stock

Get a 7-Day Free Trial

0.01

Coherus BioSciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Common Stock	Get a 7-Day Free Trial															0.01	0.01	0.01	0.01	0.01

Coherus BioSciences Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Coherus BioSciences (FRA:8C5) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coherus BioSciences Inc (FRA:8C5) » Definitions » Common Stock

Comparable Companies

Traded in Other Exchanges

CHRS:USA

Address

333 Twin Dolphin Drive, Suite 600, Redwood City, CA, USA, 94065

Website

https://www.coherus.com

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States.

Coherus BioSciences (FRA:8C5) Headlines

No Headlines